PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.85%
Negative revenue growth while MRVL stands at 6.58%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.35%
Negative gross profit growth while MRVL is at 4.54%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.23%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-11.23%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-22.75%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-21.74%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-23.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.77%
Share reduction while MRVL is at 3.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.00%
Reduced diluted shares while MRVL is at 1.30%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.80%
Dividend growth of 1.80% while MRVL is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-34.44%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-40.57%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
49.18%
10Y revenue/share CAGR under 50% of MRVL's 459.79%. Michael Burry would suspect a lasting competitive disadvantage.
130.13%
5Y revenue/share CAGR under 50% of MRVL's 525.68%. Michael Burry would suspect a significant competitive gap or product weakness.
30.62%
3Y revenue/share CAGR under 50% of MRVL's 157.52%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
101.41%
10Y OCF/share CAGR under 50% of MRVL's 329.50%. Michael Burry would worry about a persistent underperformance in cash creation.
146.61%
5Y OCF/share CAGR at 50-75% of MRVL's 257.03%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
69.41%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
323.19%
Below 50% of MRVL's 1060.07%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1889.18%
5Y net income/share CAGR above 1.5x MRVL's 155.31%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
68.97%
Below 50% of MRVL's 1336.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
181.93%
Below 50% of MRVL's 7355.62%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
25.48%
5Y equity/share CAGR above 1.5x MRVL's 8.56%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
12.20%
Below 50% of MRVL's 34.92%. Michael Burry suspects a serious short-term disadvantage in building book value.
91.76%
Dividend/share CAGR of 91.76% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
106.54%
Dividend/share CAGR of 106.54% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
88.39%
3Y dividend/share CAGR of 88.39% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-1.01%
Firm’s AR is declining while MRVL shows 19.73%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.95%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.29%
Negative asset growth while MRVL invests at 2.81%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.11%
Similar to MRVL's 1.12%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
-0.72%
Our R&D shrinks while MRVL invests at 40.66%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.93%
We cut SG&A while MRVL invests at 51.85%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.